{"id":47643,"date":"2022-08-25T08:01:40","date_gmt":"2022-08-25T06:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/"},"modified":"2022-08-25T08:01:40","modified_gmt":"2022-08-25T06:01:40","slug":"oncoinvent-initiates-radspherin-phase-2a-trial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/","title":{"rendered":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial"},"content":{"rendered":"
\n

\nFirst patient has been treated in the RAD-18-002 phase 2A clinical study\n<\/p>\n

<\/a><\/p>\n

OSLO, Norway–(BUSINESS WIRE)–Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin\u00ae. The study is conducted at two sites, the Radium Hospital in Oslo Norway and at the Uppsala University Hospital in Uppsala Sweden and will include a total of thirty patients.\n<\/p>\n

\n\u201cThe start of the RAD-18-002 phase 2A study marks an entry into the next stage of development for both our product candidate Radspherin\u00ae as well as for Oncoinvent,\u201d said Jan A. Alfheim, Chief Executive Officer of Oncoinvent. \u201cThis new study takes us a step closer to achieving our primary goal of developing an effective therapy for cancer patients suffering from peritoneal carcinomatosis.\u201d\n<\/p>\n

\nAbout the RAD-18-002 Study<\/b>\n<\/p>\n

\nThe phase 2A open-label expansion cohort of the RAD-18-002 clinical trial is designed to assess the safety, tolerability, and anti-tumor activity of Radspherin\u00ae, an \u03b1-emitting radionuclide therapy, administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC. Key objectives in the study include survival benefit as well as acute and long-term safety of the drug product candidate.\n<\/p>\n

\nAbout Oncoinvent<\/b>\n<\/p>\n

\nOncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across various cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing therapy based on alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent\u2019s lead candidate, Radspherin\u00ae, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin\u00ae is in two ongoing clinical studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information, please contact:<\/strong>
Jan A. Alfheim, Chief Executive Officer
\n
Cell: +47 46 44 00 45
\n
Email: alfheim@oncoinvent.com<\/a>\n<\/p>\n

\nIR enquiries:
\n
Courtney Turiano, Stern Investor Relations
\n
Email: Courtney.Turiano@sternir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

First patient has been treated in the RAD-18-002 phase 2A clinical study OSLO, Norway–(BUSINESS WIRE)–Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin\u00ae. The study is … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47643","6":"format-standard","7":"category-industry"},"yoast_head":"\nOncoinvent Initiates Radspherin\u00ae Phase 2A Trial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"First patient has been treated in the RAD-18-002 phase 2A clinical study OSLO, Norway–(BUSINESS WIRE)–Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin\u00ae. The study is ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T06:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220824005602\/en\/1552636\/21\/oncoinvent_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial\",\"datePublished\":\"2022-08-25T06:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/\"},\"wordCount\":366,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005602\\\/en\\\/1552636\\\/21\\\/oncoinvent_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/\",\"name\":\"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005602\\\/en\\\/1552636\\\/21\\\/oncoinvent_logo.jpg\",\"datePublished\":\"2022-08-25T06:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005602\\\/en\\\/1552636\\\/21\\\/oncoinvent_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220824005602\\\/en\\\/1552636\\\/21\\\/oncoinvent_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncoinvent-initiates-radspherin-phase-2a-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/","og_locale":"en_US","og_type":"article","og_title":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial - Pharma Trend","og_description":"First patient has been treated in the RAD-18-002 phase 2A clinical study OSLO, Norway–(BUSINESS WIRE)–Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin\u00ae. The study is ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-25T06:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220824005602\/en\/1552636\/21\/oncoinvent_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial","datePublished":"2022-08-25T06:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/"},"wordCount":366,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220824005602\/en\/1552636\/21\/oncoinvent_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/","url":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/","name":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220824005602\/en\/1552636\/21\/oncoinvent_logo.jpg","datePublished":"2022-08-25T06:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220824005602\/en\/1552636\/21\/oncoinvent_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220824005602\/en\/1552636\/21\/oncoinvent_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/oncoinvent-initiates-radspherin-phase-2a-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47643"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47643\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}